Moleculin Biotech's drug Annamycin, combined with PD-1 immune checkpoint inhibitors, significantly extended survival in preclinical pancreatic cancer models by turning immunologically 'cold' tumors 'hot' with increased T cell infiltration. Annamycin achieves higher pancreatic tissue exposure than doxorubicin, explaining its effectiveness where other topoisomerase II drugs failed. The company plans a clinical trial in 2027 to explore this combination's potential in pancreatic cancer, aiming to improve outcomes in a cancer type typically resistant to immunotherapy.
The story on Annamycin's potential in pancreatic cancer offers context from Pluang's health sector market snapshot as of Nov 11, 2026 02:41 WIB: Among 150 US health stocks, 47 rose and 103 fell. Notably, TNGX gained 5.94% at USD 24.09 with balanced buy/sell orders and a typical hold of 4 days, contrasting with IBRX which dropped 5.77% to USD 6.70 and CGC down 5.73% at USD 0.59 but held for a much longer 40 days with exclusively buy orders.
Auburn National Bancorporation, Inc. announced a quarterly cash dividend of $0.27 per share, payable on December 28, 2026, to shareholders recorded by December 10, 2026. The company is the parent of AuburnBank, an Alabama state-chartered bank with ab...
OpenTable's 2027 Quebec dining trends report shows a 9% increase in restaurant bookings, with 65% of Quebecers planning to dine out as much or more in 2027. Consumers prioritize value, local favorites, and meaningful experiences, often celebrating sm...
Pepeto's crypto presale is close to selling out, having raised $11.29 million with over 43,000 holders, driven by its fee-free trading platform and AI contract checks. Meanwhile, XRP's price has dropped to $1.11, down 72% from its peak, but analysts ...
YieldMax ETFs declared weekly distributions for their Group 1 ETFs, with distribution rates ranging from about 20% to 60% annually, depending on the ETF. These distributions reflect income generated primarily from options strategies and vary signific...
EssilorLuxottica disclosed its share capital and voting rights as of October 31, 2026, reporting 464,247,548 shares outstanding and 458,376,127 real voting rights excluding treasury shares. The company applies a 31% cap on voting rights per sharehold...
